Riccardo Giannini

List of Publications by Year
in descending order

65 papers	4,760 citations	147801 31 h-index	110387 64 g-index
67 all docs	67 docs citations	67 times ranked	4809 citing authors

#	Article	IF	Citations
1	BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5399-5404.	3.6	950
2	BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3943-3949.	3.6	482
3	Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4085-4090.	3.6	370
4	Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5175-5180.	3.6	252
5	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	8.2	231
6	TheBRAFV600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4390-4398.	3.6	213
7	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	3.6	179
8	Correlation between theBRAFV600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4197-4205.	3.6	162
9	Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90.	5.1	126
10	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	8.2	126
11	Obesity Is Associated With Low NAD⁺/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 275-283.	3.6	120
12	Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma. American Journal of Pathology, 2002, 160, 247-254.	3.8	103
13	The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3511-3516.	3.6	93
14	ALKRearrangement in a Large Series of Consecutive Nonâ€“Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. Archives of Pathology and Laboratory Medicine, 2014, 138, 1449-1458.	2.5	93
15	Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5270-5278.	3.6	71
16	RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenetic and Genome Research, 2000, 88, 56-61.	1.1	67
17	Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma. Thyroid, 2007, 17, 381-388.	4.5	64
18	Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clinical Endocrinology, 2009, 70, 946-953.	2.4	63

#	Article	IF	Citations
19	Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 177-184.	2.8	59
20	Type I Interferons Modulate the Expression of Thyroid Peroxidase, Sodium/Iodide Symporter, and Thyroglobulin Genes in Primary Human Thyrocyte Cultures. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1156-1162.	3.6	53
21	Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunochemistry in Cytologic and Pathologic Specimens. Thyroid, 2003, 13, 765-770.	4.5	51
22	Molecular testing in the diagnosis of differentiated thyroid carcinomas. Gland Surgery, 2018, 7, S19-S29.	1.1	44
23	Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene, 2004, 23, 2188-2196.	5.9	43
24	Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying theRET/PTC1 rearrangement. International Journal of Cancer, 2002, 97, 608-614.	5.1	41
25	Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3557-3575.	3.6	41
26	Cytokine Production by a New Undifferentiated Human Thyroid Carcinoma Cell Line, FB-11. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4094-4100.	3.6	38
27	Mitogenic Effects of the Up-Regulation of Minichromosome Maintenance Proteins in Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4703-4709.	3.6	38
28	CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. Modern Pathology, 2012, 25, 46-55.	5.5	35
29	Low Elasticity of Thyroid Nodules on Ultrasound Elastography Is Correlated with Malignancy, Degree of Fibrosis, and High Expression of Galectin-3 and Fibronectin-1. Thyroid, 2017, 27, 103-110.	4.5	34
30	Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1465-E1473.	3.6	33
31	Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?. Archives of Pathology and Laboratory Medicine, 2018, 142, 480-489.	2.5	33
32	Functional Characterization of the Novel T599I-VKSRdel BRAF Mutation in a Follicular Variant Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4398-4402.	3.6	32
33	BRAFStatus of Follicular Variant of Papillary Thyroid Carcinoma and its Relationship to Its Clinical and Cytological Features. Thyroid, 2010, 20, 1263-1270.	4.5	31
34	Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting. Thyroid, 2017, 27, 1267-1276.	4.5	28
35	Cytokine Production by a New Undifferentiated Human Thyroid Carcinoma Cell Line, FB-1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4094-4100.	3.6	28
36	Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma. Laboratory Investigation, 2000, 80, 1413-1419.	3.7	26

#	Article	IF	Citations
37	Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis. Oncotarget, 2017, 8, 2758-2770.	1.8	26
38	Differential Expression of Extracellular Matrix Constituents and Cell Adhesion Molecules between Malignant Pleural Mesothelioma and Mesothelial Hyperplasia. Journal of Thoracic Oncology, 2013, 8, 1389-1395.	1.1	25
39	Activation of Type I and Type II Interferon Signaling in SARS-CoV-2-Positive Thyroid Tissue of Patients Dying from COVID-19. Thyroid, 2021, 31, 1766-1775.	4.5	24
40	Molecular characterization of 54 cases of falseâ€negative fineâ€needle aspiration among 1347 papillary thyroid carcinomas. Cancer Cytopathology, 2014, 122, 751-759.	2.4	18
41	Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. Journal of Endocrinology, 2004, 182, 479-484.	2.6	17
42	Role of gene expression profiling in defining indeterminate thyroid nodules in addition to <scp>BRAF</scp> analysis. Cancer Cytopathology, 2016, 124, 340-349.	2.4	17
43	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports, 2016, 36, 1166-1172.	2.6	15
44	Molecular Diagnostics of Fine Needle Aspiration for the Presurgical Screening of Thyroid Nodules. Current Genomics, 2014, 15, 171-177.	1.6	14
45	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of thebcl-2 gene. , 1999, 81, 956-962.		13
46	A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma. Endocrine Connections, 2018, 7, 124-132.	1.9	12
47	Applications of tissue microarray technology in immunohistochemistry: A study on c-kit expression in small cell lung cancer. Human Pathology, 2004, 35, 1347-1352.	2.0	11
48	Digital gene expression profiling of a series of cytologically indeterminate thyroid nodules. Cancer Cytopathology, 2015, 123, 461-470.	2.4	11
49	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. Journal of Molecular Diagnostics, 2020, 22, 685-698.	2.8	11
50	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: A case report. Lung Cancer, 2013, 81, 297-301.	2.0	10
51	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. Lung Cancer, 2013, 81, 377-381.	2.0	8
52	Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms. Endocrine-Related Cancer, 2019, 26, 451-462.	3.1	8
53	Incidental versus clinically evident thyroid cancer: A 5â€year followâ€up study. Head and Neck, 2013, 35, 408-412.	2.0	7
54	KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncology Letters, 2014, 7, 1532-1536.	1.8	7

#	Article	IF	Citations
55	Follicular-derived neoplasms: morphometric and genetic differences. Journal of Endocrinological Investigation, 2013, 36, 1055-61.	3.3	7
56	Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis.. International Journal of Oncology, 2000, 16, 485-9.	3.3	5
57	Contraception with estradiol valerate and dienogest: adherence to the method . Open Access Journal of Contraception, 2019, Volume 10, 1-6.	1.4	5
58	Meningeal hemangiopericytoma metastatic to the adrenal gland with multiple metastases to bones and lungs: a case report. Tumori, 2004, 90, 147-50.	1.1	5
59	Novel prognostic markers for epithelioid malignant pleural mesothelioma.. Journal of Clinical Oncology, 2017, 35, e20028-e20028.	1.6	3
60	Smooth Introduction of Semantic Tagging in Genotyping Procedures. Lecture Notes in Computer Science, 2010, , 201-214.	1.3	2
61	Management of Genotyping-Related Documents by Integrated Use of Semantic Tagging. Lecture Notes in Computer Science, 2011, , 15-39.	1.3	2
62	Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction. Molecular Medicine Reports, 2016, 14, 2238-2242.	2.4	1
63	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl2 gene. International Journal of Cancer, 1999, 81, 956-962.	5.1	1
64	210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia. Journal of Thoracic Oncology, 2016, 11, S148.	1.1	0
65	A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (EGFR-TKIs): clinical features and outcome. Annals of Oncology, 2017, 28, vi56.	1.2	0